WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences:
Guggenheim 5th Annual Inflammation, Neurology & Immunology (INI) Conference
Fireside Chat Date: Tuesday, November 7, 2023
Fireside Chat Time: 3:50 PM ET
Location: New York, NY
Evercore ISI 6th Annual HealthCONx Conference
Fireside Chat Date: Thursday, November 30, 2023
Fireside Chat Time: 10:50 AM ET
Location: Miami, FL
Live webcasts of the fireside chats will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 30 days following the events.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.
Contacts:
Scott Young
(781) 208-1747
This email address is being protected from spambots. You need JavaScript enabled to view it.
Gabriella Linville-Engler
(781) 208-0160
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.03 |
| Daily Change: | 0.47 84.03 |
| Daily Volume: | 184,387,244 |
| Market Cap: | US$123.740M |
August 22, 2025 August 20, 2025 August 14, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
